Following the centralization of all Suboxone lawsuits as part of a federal MDL, lawyers must file applications by March 1 to serve in various leadership positions during the consolidated pretrial proceedings.
Manufacturers are accused of placing profits before the safety of the individuals suffering from opioid addiction, by introducing Suboxone strips without warning about the risk of dental erosion and tooth decay.
Risk of dental erosion from Suboxone was known to the drug maker, yet lawsuit indicates that users and medical community were not adequately warned about the potential side effects.
U.S. JPML Determined that Suboxone tooth decay lawsuits filed throughout the federal court system will be centralized in the Northern District of Ohio for discovery and pretrial proceedings.
Use of buprenorphine, the active ingredient in Suboxone and other opioid addiction treatments, during the first trimester of pregnancy was associated with a lower risk of most congenital malformations than methadone.
Kentucky man used the film strips for more than a decade to treat opioid use disorder, before learning the side effects of Suboxone were ruining his teeth.
Pennsylvania woman used the opioid addiction treatment for nine years before Suboxone tooth decay warnings were finally placed on the drug label, leaving her with extensive dental injuries and tooth damage.
The FDA RADARS program was originally created by Purdue Pharma, which has often been blamed for its role in creating the opioid abuse and addiction crisis.
Maine woman indicates in a recently filed Suboxone dental erosion lawsuit that she had to undergo extensive dental work after using the opioid addiction drug, which left her with permanently damaged teeth.
The Suboxone film lawsuit claims the manufacturer knew about the risk of tooth damage for years, but failed to warn patients or the medical community until the FDA forced new label warnings in 2022.
